Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIM-001 intramuscular injection in Fontaine IIb lower extremity atherosclerosis obliterans
jRCT2051220177Recruiting
- Sponsor
- Learning Health Systems Institute
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of EIM-001 in peripheral artery occlusion (PAD) and arteriosclerosis obliterans (2 arms), sponsored by Learning Health Systems Institute. Primary endpoint: Change from baseline in 6-minute walk distance at 24 weeks. Started Mar 2023; status: recruiting.
02
Drugs
EIM-001
03
Conditions
peripheral artery occlusion (PAD)arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2051220177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220177.